Sight Sciences, Inc. ((SGHT)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Sight Sciences, Inc. is conducting a pilot study titled ‘A Pilot Study of the Helix Surgical System in Subjects With Primary Open-Angle Glaucoma (POAG) and Cataract.’ The study aims to evaluate the safety of the Helix Surgical System during cataract surgery and gather preliminary evidence of its effectiveness in reducing intraocular pressure in patients with mild to moderate POAG and cataracts.
Intervention/Treatment: The study tests the Helix Surgical System, a handheld device designed to viscodilate Schlemm’s canal and collector channels, facilitating an intracanalicular scaffolding procedure to improve the aqueous outflow system in glaucomatous eyes.
Study Design: This interventional study follows a single-group model, conducted as a prospective, single-center, single-arm clinical trial. There is no masking involved, and the primary purpose is treatment.
Study Timeline: The study began on April 21, 2025, with the latest update submitted on July 15, 2025. These dates are crucial as they mark the study’s progression and the most recent data available.
Market Implications: The ongoing study could influence Sight Sciences, Inc.’s stock performance positively if the Helix Surgical System proves effective, potentially enhancing investor confidence. As the company operates in a competitive ophthalmic device market, successful results could position it favorably against competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.